Uncategorized

Hurricane Sandy Disrupts “The Disruptors”

At Real Endpoints, we know the importance of showing mothers respect – especially Mother Nature. It took a storm the magnitude of Sandy to disrupt “The Healthcare Disruptors”. But with a hurricane wrapped in...

Learn More

German Scoreboard: Payers 1, Pharma 1

AstraZeneca and other biopharmas wait with bated breath for the first drug price tags to emerge from Germany’s new early added-benefit assessment process. So who’s winning as this...

Learn More

Is France Creating Its Own NICE?

Sort of. It seems that the French are getting more comfortable with the idea of calling health-economics by its real name, and of carrying out explicit cost-effectiveness evaluations a la NICE in the UK....

Learn More

The Healthcare Round-up: 2/7 -2/13

What’s better than a box of chocolates or a dozen fair trade, organic red roses? A #healthpolicyvalentine. It’s cheaper too. Wonks and journos quickly embraced the nerdy Twitter hash tag created last week by...

Learn More

A Biosimilar Deal Making Bonanza

Affordability matters to the branded drug industry just as much — if not more — than scientific innovation. Skeptical? Look no further than the trio of biosimilar deals in December 2011. On Dec....

Learn More